Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 27, 2013, Pages 11115-11120

  Iqbal, Jameel ^a,b,c   Sun, Li ^c   Cao, Jay ^d   Yuen, Tony ^c   Lu, Ping ^c   Bab, Itai ^e   Leu, N Adrian ^a   Srinivasan, Satish ^a   Wagage, Sagie ^a   Hunter, Christopher A ^a   Nebert, Daniel W ^f   Zaidi, Mone ^c   Avadhani, Narayan G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d U S DEPARTMENT OF AGRICULTURE   (United States)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Bone formation; Osteoblast; Skeletal remodeling; Toxicology

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 HYDROXYBENZO[A]PYRENE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1B; OSTEOCLAST DIFFERENTIATION FACTOR; PROADIFEN; SILANE DERIVATIVE; TETRAMETHYLSILANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MASS; CELL CULTURE; CONTROLLED STUDY; CYP1A1 GENE; CYP1A2 GENE; CYP1B1 GENE; FEMALE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; SMOKE;

BONE FORMATION; OSTEOBLAST; SKELETAL REMODELING; TOXICOLOGY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BENZO(A)PYRENE; BONE RESORPTION; CARCINOGENS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ARYL HYDROCARBON; SMOKE; SMOKING; TETRACHLORODIBENZODIOXIN; TOBACCO;

MUS;

EID: 84879715809     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220919110     Document Type: Article

References (36)

1. Wipfli H, Samet JM (2009) Global economic and health benefits of tobacco control: Part 1. Clin Pharmacol Ther 86(3):263-271.
2. World Health Organization Collaborating Centre for Metabolic Bone Disease. (2013) FRAX (University of Sheffield, Sheffield, UK). Available at www.shef.ac.uk/FRAX.
3. Kanis JA, et al. (2005) Smoking and fracture risk: A meta-analysis. Osteoporos Int 16(2):155-162. (Pubitemid 40193202)
4. Ward KD, Klesges RC (2001) A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 68(5):259-270. (Pubitemid 32565727)
5. Szulc P, et al. (2002) Increased bone resorption in moderate smokers with low body weight: The Minos study. J Clin Endocrinol Metab 87(2):666-674. (Pubitemid 34158235)
6. Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL (2000) Smoking and bone metabolism in elderly women. Bone 27(3):429-436. (Pubitemid 30658128)
7. Ilvesaro J, Pohjanvirta R, Tuomisto J, Viluksela M, Tuukkanen J (2005) Bone resorption by aryl hydrocarbon receptor-expressing osteoclasts is not disturbed by TCDD in shortterm cultures. Life Sci 77(12):1351-1366. (Pubitemid 40943676)
8. Singh SU, et al. (2000) Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol 167(1):183- 195.
9. Kung MH, Yukata K, O'Keefe RJ, Zuscik MJ (2012) Aryl hydrocarbon receptormediated impairment of chondrogenesis and fracture healing by cigarette smoke and benzo(a)pyrene. J Cell Physiol 227(3):1062-1070.
10. Voronov I, Li K, Tenenbaum HC, Manolson MF (2008) Benzo[a]pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-kappaB. Biochem Pharmacol 75(10):2034-2044.
11. DiNatale BC, Schroeder JC, Perdew GH (2011) Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Mol Carcinog 50(3):173-183.
12. Vogel CF, Matsumura F (2009) A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family. Biochem Pharmacol 77(4):734-745.
13. Vogel CF, et al. (2011) Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Arch Biochem Biophys 512(1):78-86.
14. Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF (2005) Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration. Biochem Pharmacol 70(2):300-307. (Pubitemid 40814411)
15. Naruse M, et al. (2004) Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: Suppression of osteoclast differentiation factor in osteogenic cells. Biochem Pharmacol 67(1):119-127. (Pubitemid 37518539)
16. N'jai AU, Larsen MC, Bushkofsky JR, Czuprynski CJ, Jefcoate CR (2011) Acute disruption of bone marrow hematopoiesis by benzo(a)pyrene is selectively reversed by aryl hydrocarbon receptor-mediated processes. Mol Pharmacol 79(4):724-734.
17. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13(7):791-801.
18. Abe E, et al. (2003) TSH is a negative regulator of skeletal remodeling. Cell 115(2):151-162. (Pubitemid 37329579)
19. Wejheden C, et al. (2010) Transgenic mice with a constitutively active aryl hydrocarbon receptor display a gender-specific bone phenotype. Toxicol Sci 114(1):48-58.
20. Galván N, Jaskula-Sztul R, MacWilliams PS, Czuprynski CJ, Jefcoate CR (2003) Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liver. Toxicol Appl Pharmacol 193(1):84-96. (Pubitemid 37373768)
21. Galván N, et al. (2005) Induction of CYP1A1 and CYP1B1 in liver and lung by benzo(a) pyrene and 7,12-d imethylbenz(a)anthracene do not affect distribution of polycyclic hydrocarbons to target tissue: Role of AhR and CYP1B1 in bone marrow cytotoxicity. Toxicol Appl Pharmacol 202(3):244-257. (Pubitemid 40164278)
22. Uno S, et al. (2006) Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 69(4):1103-1114.
23. Nebert DW, Wikvall K, Miller WL (2013) Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 368(1612):20120431.
24. Lees RL, Sabharwal VK, Heersche JN (2001) Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 28(2):187-194. (Pubitemid 32143685)
25. Bruno RD, Njar VC (2007) Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. Bioorg Med Chem 15(15):5047-5060. (Pubitemid 46880385)
26. Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227(2):115-124. (Pubitemid 41174580)
27. Jefcoate CR, et al. (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr (27):95-112.
28. Sissung TM, Price DK, Sparreboom A, Figg WD (2006) Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 4(3):135-150.
29. Labrecque MP, et al. (2012) Distinct roles for aryl hydrocarbon receptor nuclear translocator and ah receptor in estrogen-mediated signaling in human cancer cell lines. PLoS ONE 7(1):e29545.
30. Nebert DW, Karp CL (2008) Endogenous functions of the aryl hydrocarbon receptor (AHR): Intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J Biol Chem 283(52):36061-36065.
31. Kasai A, et al. (2006) High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res 66(14):7143-7150. (Pubitemid 44197692)
32. Yin XF, Chen J, Mao W, Wang YH, Chen MH (2012) A selective aryl hydrocarbon receptor modulator 3,3′-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res 31:46.
33. Lindsey S, Papoutsakis ET (2012) The evolving role of the aryl hydrocarbon receptor (AHR) in the normophysiology of hematopoiesis. Stem Cell Rev 8(4):1223-1235.
34. Kagan R (2012) The tissue selective estrogen complex: A novel approach to the treatment of menopausal symptoms. J Womens Health (Larchmt) 21(9):975-981.
35. Dragin N, et al. (2008) Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. Mol Pharmacol 73(6):1844-1856.
36. Sun L, et al. (2006) FSH directly regulates bone mass. Cell 125(2):247-260.